TY - JOUR T1 - A Cross-Sectional Study Evaluating Tick-borne Encephalitis Vaccine Uptake and Timeliness Among Adults in Switzerland JF - medRxiv DO - 10.1101/2021.02.04.21251135 SP - 2021.02.04.21251135 AU - Kyra D. Zens AU - Vasiliki Baroutsou AU - Philipp Sinniger AU - Phung Lang Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/08/2021.02.04.21251135.abstract N2 - Objectives The goal of this study was to evaluate timeliness of Tick-borne Encephalitis vaccination uptake among adults in Switzerland.Methods In this cross-sectional survey, we collected vaccination records from randomly selected adults 18-79 throughout Switzerland. Of 4,626 participants, data from individuals receiving at least 1 TBE vaccination (n=1875) were evaluated. We determined year and age of first vaccination and vaccine compliance, evaluating dose timeliness. Participants were considered “on time” if they received doses according to the recommended schedule ± a 15% tolerance period.Results 45% of participants received their first TBE vaccination between 2006 and 2009. 25% were first vaccinated aged 50+ (mean age 37). More than 95% of individuals receiving the first dose also received the second; ∼85% of those receiving the second dose received the third. For individuals completing the primary series, 30% received 3 doses of Encepur, 58% received 3 doses of FSME-Immun, and 12% received a combination. According to conventional schedules, 88% and 79% of individuals received their second and third doses “on time”, respectively. 20% of individuals receiving Encepur received their third dose “too early”. Of individuals completing primary vaccination, 19% were overdue for a booster. Among the 31% of subjects receiving a booster, mean time to first booster was 7.1 years.Conclusions We estimate that a quarter of adults in Switzerland were first vaccinated for TBE aged 50+. Approximately 80% of participants receiving at least one vaccine dose completed the primary series. We further estimate that 66% of individuals completing the primary series adhered to an “ideal” TBE vaccination schedule.Competing Interest StatementPL received compensation for a presentation at a Pfizer training workshop; Pfizer also covered her cost to attend the ISW-TBE meeting (International Scientific Working group on TBE) in 2019.Funding StatementThis study was supported by a grant from Pfizer WI233989. The funders had no role in the design, implementation or evaluation of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Office of Data Protection and the Ethics Committee of the Canton of Zurich.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data used in this study can be made available upon request. ER -